Olstein Capital Management L.P. Decreases Stake in Thermo Fisher Scientific Inc. $TMO

Olstein Capital Management L.P. cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 20.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,400 shares of the medical research company’s stock after selling 1,600 shares during the quarter. Olstein Capital Management L.P.’s holdings in Thermo Fisher Scientific were worth $3,708,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. JPL Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the third quarter valued at approximately $28,000. Beacon Financial Strategies CORP acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Olistico Wealth LLC acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $29,000. Cloud Capital Management LLC purchased a new position in Thermo Fisher Scientific during the third quarter worth about $31,000. Finally, KERR FINANCIAL PLANNING Corp purchased a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at approximately $38,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 5,800 shares of company stock worth $2,963,544. Insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. DZ Bank initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 price target on the stock. Jefferies Financial Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Citigroup upped their price target on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a research note on Friday, January 30th. UBS Group restated a “neutral” rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $620.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $623.05.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $473.58 on Friday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The stock has a market capitalization of $175.99 billion, a price-to-earnings ratio of 26.04, a price-to-earnings-growth ratio of 2.09 and a beta of 0.88. The business has a 50-day moving average of $493.53 and a 200 day moving average of $546.70. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.